MORE►
oncology
Left: McKesson CEO Brian Tyler; Right: Florida Cancer Specialists CEO Nathan H. Walcker [Photos: McKesson/FCS]
North Texas’ McKesson To Acquire Majority Stake in Florida Cancer Healthcare Network for $2.49 Billion
by Lance Murray | Aug 26, 2024
Florida-based Core Ventures was established by the Florida Cancer Specialists & Research Institute, a physician-owned community oncology practice. With the multi-billion-dollar acquisition, CORE Ventures will join McKesson's US Oncology Network to advance "affordable cancer care and better patient outcomes."
by Lance Murray |
Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
MORE►
by Lance Murray |
Mar 7, 2023
NanOlogy said the new patent covers a method of treating cancer by intratumoral administration of large surface area microparticle taxanes in combination with systemic administration of immune checkpoint inhibitors. “The goal is to identify which combinations can increase the immune response, thereby increasing the overall solid tumor response to treatment," said NanOlogy Chief Medical Officer Gere DiZerega.
MORE►
by Quincy Preston |
Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
Ontada president Derek Rago [Photo: McKesson]
McKesson Launches New Oncology Tech and Insights Business to Transform the Fight Against Cancer
by Alex Edwards | Dec 9, 2020
Ontada builds on McKesson's long history in community oncology. The new business will combine McKesson's real-world data and research capabilities, technology, and ties to the national community oncology network to transform cancer care.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
by Payton Potter |
May 2, 2019
Using a patient's molecular makeup, Caris and Pharmatech aim to find the perfect clinical trial for each cancer patient—and enroll them in as little as 10 days.
MORE►
by Julia Batlle |
Feb 14, 2017
The Foley and Lardner LLP award recognizes effective business models and strategies for cancer care providers.
MORE►
